What did Cowen change in the March 18, 2026 AZN analyst rating update?

Cowen & Co. **maintained** a Buy on AstraZeneca PLC (AZN) on March 18, 2026. The firm reaffirmed its positive view but did not issue a new price target. The update reinforced confidence rather than altering valuation assumptions.

How did the market react to the AZN analyst rating maintenance?

The market moved modestly after the AZN analyst rating note. AZN fell **0.93%** or **$1.76** since the update, showing investors treated Cowen’s note as reassurance rather than fresh bullish news.

Did Cowen publish a new AZN price target with the rating?

No. Cowen maintained its Buy on March 18, 2026 without publishing a new AZN price target. That absence means the note functioned as conviction reinforcement rather than a valuation revision.

How should investors use the AZN analyst rating in decisions?

Treat the AZN analyst rating as one input. A maintained Buy signals analyst confidence but not a guarantee. Combine this rating with earnings, clinical timelines, and risk tolerance before adjusting positions.

Analyst Ratings

Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026

ByHuzaifa Zahoor March 19, 2026March 19, 2026

Cowen & Co. maintained a Buy on AstraZeneca PLC (AZN) on March 18, 2026 at 09:24 AM, the main AZN analyst rating update this week. Cowen highlighted AstraZeneca’s history of innovation as a source of potential upside. StreetInsider published Cowen’s note. The action left the rating unchanged but reinforced positive analyst conviction. The stock showed a modest move, down 0.93% or $1.76 since the update. Market cap is $146,152,979,602. Meyka AI rates AZN with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.